TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04952753
Drug: Modified FOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil \[continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and oxaliplatin \[administered IV\]
Study: NCT04952753
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil \[continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and irinotecan \[administered IV\]
Study: NCT06209177
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile normal saline (0.9% NaCl for sc injection)
Study: NCT06521762
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo oral tablet
Study: NCT06521762
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids will be given in conjunction with study drug or placebo
Study: NCT05980949
Drug: KarXT
Approvals — FDA: no, EMA: no, PMDA: no
Description: KarXT 20/2 mg TID (total daily dose \[TDD\] 60/6 mg) KarXT 30/3 mg TID (TDD 90/9 mg) KarXT 40/4 mg TID (TDD 120/12 mg) KarXT 50/5 mg TID (TDD 150/15 mg) KarXT 66.7/6.67 mg TID (TDD 200/20 mg)
Study: NCT04168203
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo oral tables twice daily for a duration of 12 months
Study: NCT00044837
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06068478
Drug: Qingzhu Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the 72-hour treatment period, participants will receive 9 sacks of Qingzhu granules.Oral administration, 1 sack (6g) per time, 3 times daily.
Study: NCT06068478
Drug: Qingzhu Granules Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the 72-hour treatment period, participants will receive 9 sacks of Qingzhu granules Placebo.Oral administration, 1 sack (6g) per time, 3 times daily.
Study: NCT06598527
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: platinum-based double-agent chemotherapy
Study: NCT04761770
Drug: conditioning regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Based on the Geriatric assessment.~1. HCT-CI/Age ≤4 AND no IADL impairment (less vulnerable/fit) -\> Myeloablative (MA) regimen~2. HCT-CI/Age \>4 AND/OR any IADL impairment (more vulnerable) -\> Reduced-intensity (RIC)/Nonmyeloablative (NMA) regimen
Study: NCT06096857
Drug: Placebo (sucrose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freeze dried packet to be reconstituted in water
Study: NCT05579509
Drug: Midazolam and Fentanyl
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prior to the start of the nerve block, patients in Arm 1 will receive titrated pharmacological sedation with IV midazolam with a goal of achieving moderate sedation. If pain is felt despite subcutaneous lidocaine, IV fentanyl may be administered with a goal of achieving moderate sedation with analgesia.
Study: NCT04884490
Drug: Co-trimoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tab. Co-trimoxazole 960 mg (trimethoprim 160mg + sulphamethoxazole 800mg) thrice (8 hourly) daily for 7 days orally.
Study: NCT04884490
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo thrice (8 hourly) daily for 7 days orally.
Study: NCT06435702
Drug: androgen deprivation therapy only
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The ADT regimen was either a gonadotropin-releasing hormone analog agonist or a gonadotropin-releasing hormone antagonist.The ADT administration type, frequency, and dose were determined by the investigator.
Study: NCT04736199
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated tablet matching Darolutamide in appearance, oral administration
Study: NCT06347016
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile normal saline (0.9% NaCl)
Study: NCT05984745
Drug: Coenzyme Q10 Forte® capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coenzyme Q10 in the form of soft gelatin capsules, each capsule containing 100 mg
Study: NCT06088979
Drug: TOUR006 - 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOUR006 20 MG
Study: NCT06088979
Drug: TOUR006 - 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOUR006 - 50 MG
Study: NCT06131983
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: calculated volume to match active treatment by IV infusion
Study: NCT06179511
Drug: AZD9829
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9829 will be administered by IV infusion
Study: NCT04826094
Drug: Rehydragel®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant. Aluminum hydroxide fluid gel. 500 µg per dose. Administered by intramuscular injection.
Study: NCT04826094
Drug: Placebo (IM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride (sterile saline). Administered by intramuscular injection.
Study: NCT04826094
Drug: Placebo (TCl)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous application (needle-free skin patch). 0.9% sodium chloride (sterile saline) added to gauze pad at site of injection.
Study: NCT05083364
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile normal saline (0.9% NaCl) for sc injection
Study: NCT04824911
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 20 mg/day.
Study: NCT06406400
Drug: AZD4041
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1a: Healthy participants will receive AZD4041 (Dose 1) orally on Day 1 and Day 9.~Part 1b: Healthy participants will receive AZD4041 (Dose 2) orally on Day 1 as a single dose.~Part 2: Participants with OUD will receive daily doses of AZD4041 from Days 1 to 7.
Study: NCT06406400
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1b: Healthy participants will receive matching placebo orally on Day 1 as a single dose.~Part 2: Participants with OUD will receive placebo daily from Days 1 to 7.
Study: NCT05726032
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized to Empagliflozin 10 mg or placebo for 14 days. A 14 day washout period follows and then participants is crossed over to the alternate treatment for 14 days.
Study: NCT05157126
Drug: Gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liquid gentamicin administered at the open fracture site
Study: NCT05157126
Drug: normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline administered at the open fracture site
Study: NCT04283656
Drug: Spironolactone 100mg
Normalized name: SPIRONOLACTONE 100MG TAB
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg orally for two doses, twice-daily
Study: NCT04283656
Drug: Estradiol 2mg
Normalized name: ESTRADIOL 2MG TAB
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4mg orally for two doses, twice-daily
Study: NCT03943901
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy drug, alkylating agent
Study: NCT03943901
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy drug, anthracycline antibiotic
Study: NCT05584111
Drug: STC-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: STC-15 oral capsules various dosing regimen in 3-week cycles
Study: NCT05371093
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT05371093
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT05208944
Drug: 6-Thio-2'-Deoxyguanosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: small molecule telomere targeting agent
Study: NCT06290934
Drug: Placebo-to-match GS-1427
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05242315
Drug: Envarsus Oral Product
Normalized name: Envarsus Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: as described in arm/group description
Study: NCT04671836
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be purchased and encapsulated by the pharmacy at the Zucker Hillside Hospital.
Study: NCT06205381
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution with no active ingredients
Study: NCT06188624
Drug: TQB2922 for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2922 for injection is administrated to patients with advanced cancers, 28 days as a treatment cycle
Study: NCT06450197
Drug: AZD7798
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7798
Study: NCT05248997
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of matching placebo
Study: NCT05364684
Drug: LUM-201
Approvals — FDA: no, EMA: no, PMDA: no
Description: LUM-201 (ibutamoren mesylate) is an oral growth hormone secretagogue.
Study: NCT06289673
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT as part of Intrathecal triple therapy.
Study: NCT05695898
Drug: XmAb22841
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given intravenously (IV)
Study: NCT04838769
Drug: alpha blocker and 5-alpha reductase inhibitor
Normalized name: 5.alpha.-hydroxy laxogenin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects assigned to dual drug therapy will be treated with the local formulary preferred choice of commercially available urinary selective alpha blocker and 5-alpha reductase inhibitor. This arm will therefore represent local standard of care.
Study: NCT06542250
Drug: AZD5492
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD8/TCR based T-cell engaging antibody targeting CD20, which is administered subcutaneously
Study: NCT05494736
Drug: MK-8527
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8527 capsule taken by mouth.
Study: NCT05368285
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Administration
Study: NCT06356259
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT06078592
Drug: BRIDIN-plus Eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRIDIN-plus Eye drops
Study: NCT06138743
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: calculated volume to match active treatment by IV infusion
Study: NCT05394675
Drug: DS-9606a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT06188520
Drug: AZD8421
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDK2 inhibitor
Study: NCT06400472
Drug: LY4170156
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous
Study: NCT06046859
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be randomized to take Fluoxetine (10mg by mouth per day for first 14 days then 20 mg by mouth for 9 months). The randomized drug will be prescribed by the study team on the day of randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy at the 2 week, 3 month, and 6 month follow-up visits
Study: NCT06046859
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: When a patient is enrolled, the inpatient research pharmacy will dispense the appropriately randomized medication in a visually similar, over-encapsulated form as Fluoxetine
Study: NCT06360354
Drug: Modified FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified FOLFIRINOX consists of irinotecan, 5-FU, LV, and oxaliplatin administered IV
Study: NCT06433505
Drug: [14C] BMS-986365
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days.
Study: NCT06433505
Drug: [14C] BMS-986409 + BMS-986410
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06433505
Drug: [14C] BMS-986410 + BMS-986409
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05039619
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching obinutuzumab will be administered by IV on Day 1, Day 14, Week 24, Week 26 and Week 52.
Study: NCT05039619
Drug: Acetaminophen/paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1000 mg will be administered as pre-medication prior to infusions.
Study: NCT06502366
Drug: BDA MDI HFO 160/180 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/albuterol pressurized inhalation suspension, HFO
Study: NCT06502366
Drug: BDA MDI HFA 160/180 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/albuterol pressurized inhalation suspension, HFA
Study: NCT06502366
Drug: Placebo MDI HFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pressurized inhalation suspension, HFA
Study: NCT05047263
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, once daily, oral
Study: NCT06548139
Drug: Natural full human monoclonal antibody CBB 1 injection 50.0µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active ingredient: natural full human monoclonal antibody CBB 1 containing 0.5 mg / ml per dose (2.5ml) Ingredients: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection
Study: NCT06548139
Drug: Natural full human monoclonal antibody CBB 1 injection 100.0µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active ingredient: natural full human monoclonal antibody CBB 1 containing 0.5 mg / ml per dose (2.5ml) Ingredients: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection
Study: NCT02254915
Drug: Bacillus Calmette-Guérin
Normalized name: Bacillus Calmette-Guérin (BCG) vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation of BCG.
Study: NCT06468462
Drug: WHO-recommended periodic presumptive treatment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg po cefixime plus 1 gram azithromycin po under direct observation
Study: NCT06468462
Drug: Doxycycline post-exposure prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg po doxycycline within 24-72 hours after condomless anal or vaginal sex as frequently as daily
Study: NCT06500702
Drug: SAR442970
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR442970 treatment
Study: NCT06500702
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo treatment
Study: NCT06502379
Drug: AZD8965
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8965 will be administered orally.
Study: NCT06600711
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical in consistency, appearance, and taste to nitazoxanide suspension. 5 mL suspension given 2x/day for 3 days
Study: NCT06601296
Drug: IMSA101
Approvals — FDA: no, EMA: no, PMDA: no
Description: All enrolled patients to undergo the following treatment:~SOC treatment: Nivolumab 480 mg monthly PULSAR: 36 Gy in 3 fractions, Q4weeks IMSA101: five intra-tumoral injections of one of the progressive lesions at 1200 mcg (C1D1, C1D8, C1D15, C2D1, C3D1)
Study: NCT06662539
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to petrelintide will be taken by participants once weekly as a self-administered subcutaneous injection.
Study: NCT06586515
Drug: LY3962673
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT06586515
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously.
Study: NCT05131971
Drug: GSK3888130B
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3888130B will be administered.
Study: NCT05131971
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered.
Study: NCT06691113
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous
Study: NCT06785402
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: D5W (placebo)
Study: NCT04848220
Drug: Temanogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single intravenous dose of temanogrel on Day 1 (Day 1 of PCI procedure)
Study: NCT04848220
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single intravenous dose of temanogrel matching placebo on Day 1
Study: NCT06507436
Drug: Herombopag placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herombopag placebo tablets; dose 1 or dose 2, for 5 days
Study: NCT06010758
Drug: Listerine Experimental Mouthwash
Normalized name: Listerine Mouthwash Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Experimental Mouthwash twice a day, morning and night.
Study: NCT06010758
Drug: Listerine Total Care Zero
Normalized name: Listerine Total Care Zero Alcohol Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Total Care Zero mouthwash twice a day, morning and night.
Study: NCT05803863
Drug: Myatro
Approvals — FDA: no, EMA: no, PMDA: no
Description: myopia control with 0.01% atropine drops
Study: NCT06658964
Drug: Cohort 2: JMKX003142 and rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: JMKX003142: Dose: 6 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg rifampicin once: Day14, once only in the morning.~Rifampicin：Dose: 600mg once；Day5-Day13 and Day15-Day17, QD
Study: NCT06660940
Drug: Keluoxin Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment period (52 weeks):Keluoxin Capsules, 4 capsules/time, swallow with warm water after meals, 3 times/day
Study: NCT06660940
Drug: Keluoxin Capsule Simulants
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment period (52 weeks):Keluoxin Capsule Simulants, 4 capsules/time, swallow with warm water after meals, 3 times/day
Study: NCT05033639
Drug: Melatonin 6 MG
Normalized name: melatonin 6 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin is an endogenously produced indolamine principally synthesized in the pineal gland from serotonin. It is described as a ubiquitous molecule which plays a vital role in the physiologic function of the body. Melatonin, also known as N-acetyl-5-methoxytryptamine which has a a) immunomodulator; b) free radical scavenger; c) prevention of oxidative stress and d) anti-inflammatory7-10.
Study: NCT06668571
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will receive 1:1 single IV normal saline/placebo (n=15) 40-min infusion in an MRI scanner, followed by an optional open-label ketamine infusion (available to everyone) 1-7 days after the initial treatment
Study: NCT06660017
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this arm will receive unmedicated syrup solution dispensed as 20mg/5ml 4 times a day in addition to receiving one of the following standard treatments; Magic Mouthwash, saliva substitute rinses, over-the-counter remedies including honey or salt and soda rinses, non-steroidal anti-inflammatory drugs (NSAIDS), or opioid medications.
Study: NCT04707768
Drug: Mircera®
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous administration
Study: NCT05362773
Drug: MGD024
Approvals — FDA: no, EMA: no, PMDA: no
Description: MGD024 is a CD123 x CD3 bispecific DART® molecule designed to target CD123-expressing leukemic cells for elimination by CD3-expressing T lymphocytes.
Study: NCT06658626
Drug: [¹⁴C]Enlicitide chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Injection
Study: NCT06673667
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral drug
Study: NCT06752668
Drug: ORX750
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORX750 capsule.
Study: NCT06752668
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORX750 matching placebo capsule.
Study: NCT05319730
Drug: Acetaminophen (or equivalent)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered per product label.
Study: NCT05319730
Drug: Supportive care measures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Artificial tear drops or gel may be given as a supportive care for Ocular Surface Toxicity.
Study: NCT06683508
Drug: LY3549492
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06683508
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06690242
Drug: MT1013
Approvals — FDA: no, EMA: no, PMDA: no
Description: MT1013 is a novel calcimimetic agent
Study: NCT06690242
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The measure does not contain the active ingredients
Study: NCT05638802
Drug: DS-7011a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg intravenous dose to be administered every 4 weeks at baseline (Day 1), Day 29, and Day 57
Study: NCT05638802
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline intravenous solution administered every 4 weeks at baseline (Day 1), Day 29, and Day 57
Study: NCT06718426
Drug: Fertitonex capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fertitonex which contains L- carnitine L-tartarate 300 mg, L-arginine 241mg, vitamin B6 1.1 mg, vitamin B12 1.7 mcg, vitamin D3 2 mcg, vitamin E 6.5 mg, vitamin C 60 mg, selenium 28 mcg, zinc 7.5 mg, folic acid 300 mcg and CoQ 10 enzyme 7.5 mg in each capsule. The dose will be one capsule twice daily for 3 months.
Study: NCT06718426
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo oral capsule. the dose is twice daily for 3 months
Study: NCT05644977
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets